Clinical Data buying Genaissance

In a move to penetrate the molecular diagnostics market, Clinical Data has struck a deal to buy Genaissance Pharmaceuticals for $56 million in stock. Clinical Data makes diagnostic tools for laboratories and doctors offices and sees the acquisition as a natural fit. After the deal closes, Genaissance shareholders will own about 40% of the combined company. Genaissance has two molecular tests on the market with several more in development.

- read this story from the AP for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.